Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-EN Version v5-FR
Language English French
Date Updated 2023-02-14 2023-02-06
Drug Identification Number 00828602 00828602
Brand name 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION
Common or Proper name 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION
Company Name BAXTER CORPORATION BAXTER CORPORATION
Ingredients DEXTROSE LIDOCAINE HYDROCHLORIDE DEXTROSE LIDOCAINE HYDROCHLORIDE
Strength(s) 50MG 4MG 50MG 4MG
Dosage form(s) SOLUTION SOLUTION SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 500mL bag 500mL bag
ATC code C01BB C01BB
ATC description ANTIARRHYTHMICS, CLASS I AND III ANTIARRHYTHMICS, CLASS I AND III
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2023-01-09 2023-01-09
Actual start date 2023-01-09 2023-01-09
Estimated end date 2023-02-13 2023-02-13
Actual end date 2023-02-13
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Baxter product LIDOCAINE HYDROCHLORIDE 0.4% AND 5% DEXTROSE INJECTION (250 mL bags) is available as a substitute. Baxter product LIDOCAINE HYDROCHLORIDE 0.4% AND 5% DEXTROSE INJECTION (250 mL bags) is available as a substitute.
Health Canada comments